Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than +100 active research sites across the globe. It is the second-largest clinical research site organization in the world. Its member companies have over 100 years of combined experience and have completed more than 7,000+ studies helping to evaluate thousands of new drugs and treatments in more than 15,000,000 patients. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.

hyperCORE and its partner members look to elevate the highly fragmented and inherently inefficient site model – something each member has already done on a singular level will now be achieved on a much larger scale. By combining their strengths and through further integration, the alliance is sure to turn some heads. Currently, the hyperCORE super network has more than +100 sites across 2 continents.

hyperCORE International is 100% committed in leading the charge in direct-to-patient clinical research. Also known as decentralized clinical trials (DCT), direct-to-patient research is in the best interest of the patients we serve as well as the entire clinical trial industry. Not only do these trials broaden accessibility, thereby increasing trial enrollment, but they also simplify the work load for trial teams. We aim to engage with industry and technology such that decentralized trials become more commonplace, and provide a win-win scenario for all involved.

Our Mission Statement

To accelerate clinical research through innovative partnerships between industry-leading clinical trial companies that will ultimately improve the health and well-being of diverse populations across the globe.

hyperCORE's Code of Ethics


​Dr. Jeff Kingsley

Chief Operational Officer

Dr. Kingsley received his Bachelor of Science degree from the University of Scranton in 1995 with concentrations in biology, chemistry, history, and cultural anthropology, and his Master of Science degree in 1997 in biochemistry.  His medical degree was received from the Philadelphia College of Osteopathic Medicine in 2001 and his MBA was received from Emory University’s Goizueta Business School in 2011.  Dr. Kingsley has been faculty with the Columbus Regional Health Family Medicine Residency as well as Director of Family Medicine and Urgent Care.  He currently holds faculty appointments with the Mercer School of Medicine and the Philadelphia College of Osteopathic Medicine Georgia.

Dr. Kingsley is founder and CEO of IACT Health, a research management organization, and 15 wholly owned and integrated clinical research offices in multiple cities in two states. The family of companies conduct phase Ib through IV research in nearly every medical specialty; inpatient and outpatient; pharmaceutical, biotechnology, and medical device. He has dedicated his career to clinical research since 2006.

Dr. Kingsley is the current COO and Chair of the Board of Directors of hyperCORE International, LLP, “Centers of Research Excellence”.  IACT Health is one of eight companies partnered to form a new super network of highly experienced and awarded clinical research sites called hyperCORE International.  Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.

​He is also the past Chair of the Board of Trustees for the Association for Clinical Research Professionals which represents more than 13,000 clinical research professionals internationally.  He is the former Treasurer for ACRP and APCR, Past President of ABSAME, sits on three additional Boards, and participates on numerous other local, national, and international committees. Dr. Kingsley obtained his CPI in 2009 and his FACRP in 2017.

He enjoys each day with his wife Christine and four beautiful children. 


Mark Lacy

Chairman of the Board

Mark Lacy is founder and CEO of Benchmark Research – a growing and dynamic firm with a network of quality investigative research sites throughout the United States. Mr. Lacy’s active participation with the Association of Clinical Research Professionals (ACRP) has encompassed serving as Chair of the Site Manager’s Forum, Chair of the Finance Committee, being elected to the Board of Trustees; and in 2005 being honored as a recipient of the Meritorious Service Award. Mr. Lacy also serves on the Board of Advisors for The Center for Information & Study on Clinical Research Participation (CISCRP), and as a member of the Executive Committee for the PharmaTimes U.S. Clinical Researcher of the Year competition.

In 2010, Mr. Lacy was selected by Entrepreneur Magazine as one of the top four “Established Entrepreneurs” for his success in growing Benchmark Research, and was recognized in 2011 by PharmaVoice as one of the 100 most Inspiring People. This entrepreneurial approach has extended into his formation of VaxCorps, a nationally prominent research network focusing on vaccines, of which he is the CEO.  He is also emerging as a leader in real estate development in Texas with office buildings in Austin and ocean front resort properties on the Texas coast.

​Prior to founding Benchmark Research, Mr. Lacy earned a B.A. degree from The University of Texas at Austin (Plan II Program, Summa Cum Laude); and held several prominent positions in state and national politics, including service under a Presidential Administration.


We are responsible for owning our decisions and outcomes and holding others accountable when they are not.


We anticipate the needs and cater to our industry clients.


We build and value relationships so we have meaningful partnerships.


We strive for excellence and do not accept the status quo.


We are honest and transparent.


We are leaders and experts in our field.


With enthusiasm, we plan, do, check, and act.


We seek to provide access to all, and focus on patient experience and outcomes.


We seek to disrupt and identify opportunities to overcome challenges.


We demonstrate the highest esteem for one another.

Phase 1 Capabilities